{
  "trial_id": "NCT00329030",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, diagnosis of lymphoma subtype, CD20+ status, number of prior chemotherapy regimens, disease status (primary induction failure, first relapse, or second complete remission), bone marrow involvement percentage, cardiac function (left ventricular ejection fraction), hepatic function (bilirubin, ALT, AST levels), renal function (creatinine, creatinine clearance), pulmonary function (DLCO, FEV1, FVC), CD34+ cell count in autologous graft, Karnofsky performance score, prior malignancies, pregnancy status, HIV status, prior autologous or allogeneic HSCT, evidence of MDS/AML, prior severe reaction to Rituxan or Filgrastim, prior radioimmunotherapy, hypersensitivity to murine proteins.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "KPS",
          "Karnofsky performance score"
        ],
        [
          "No. of prior therapies",
          "number of prior chemotherapy regimens"
        ],
        [
          "Disease status at transplantation",
          "disease status (primary induction failure, first relapse, or second complete remission)"
        ]
      ],
      "remaining_reference_features": [
        "Received transplantation",
        "Eligible for study",
        "Male",
        "Race"
      ],
      "remaining_candidate_features": [
        "sex",
        "diagnosis of lymphoma subtype",
        "CD20+ status",
        "bone marrow involvement percentage",
        "cardiac function (left ventricular ejection fraction)",
        "hepatic function (bilirubin, ALT, AST levels)",
        "renal function (creatinine, creatinine clearance)",
        "pulmonary function (DLCO, FEV1, FVC)",
        "CD34+ cell count in autologous graft",
        "prior malignancies",
        "pregnancy status",
        "HIV status",
        "prior autologous or allogeneic HSCT",
        "evidence of MDS/AML",
        "prior severe reaction to Rituxan or Filgrastim",
        "prior radioimmunotherapy",
        "hypersensitivity to murine proteins"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Sex, Race, Disease status (primary induction failure, first relapse, second complete remission), Number of prior chemotherapy regimens, Bone marrow involvement percentage, Cardiac function (left ventricular ejection fraction), Hepatic function (bilirubin, ALT, AST levels), Renal function (creatinine, creatinine clearance), Pulmonary function (DLCO, FEV1, FVC), Karnofsky performance score, CD34+ cell count in autologous graft, HIV status, Prior malignancies, Prior severe reaction to Rituxan or Filgrastim, Prior radioimmunotherapy, Hypersensitivity to murine proteins.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race",
          "Race"
        ],
        [
          "KPS",
          "Karnofsky performance score"
        ],
        [
          "Disease status at transplantation",
          "Disease status (primary induction failure, first relapse, second complete remission)"
        ],
        [
          "No. of prior therapies",
          "Number of prior chemotherapy regimens"
        ]
      ],
      "remaining_reference_features": [
        "Received transplantation",
        "Eligible for study",
        "Male"
      ],
      "remaining_candidate_features": [
        "Sex",
        "Bone marrow involvement percentage",
        "Cardiac function (left ventricular ejection fraction)",
        "Hepatic function (bilirubin, ALT, AST levels)",
        "Renal function (creatinine, creatinine clearance)",
        "Pulmonary function (DLCO, FEV1, FVC)",
        "CD34+ cell count in autologous graft",
        "HIV status",
        "Prior malignancies",
        "Prior severe reaction to Rituxan or Filgrastim",
        "Prior radioimmunotherapy",
        "Hypersensitivity to murine proteins"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Sex, Ethnic Origin, Karnofsky performance score, Diagnosis, Disease status, Number of prior regimens of chemotherapy, Bone marrow involvement, Cardiac function, Hepatic function, Renal function, Pulmonary function, Autologous graft CD34+ cells/kg, Prior malignancies, HIV seropositivity, Pregnancy or breastfeeding status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "KPS",
          "Karnofsky performance score"
        ],
        [
          "Disease status at transplantation",
          "Disease status"
        ],
        [
          "No. of prior therapies",
          "Number of prior regimens of chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Received transplantation",
        "Eligible for study",
        "Male",
        "Race"
      ],
      "remaining_candidate_features": [
        "Sex",
        "Ethnic Origin",
        "Diagnosis",
        "Bone marrow involvement",
        "Cardiac function",
        "Hepatic function",
        "Renal function",
        "Pulmonary function",
        "Autologous graft CD34+ cells/kg",
        "Prior malignancies",
        "HIV seropositivity",
        "Pregnancy or breastfeeding status."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, Karnofsky performance score, diagnosis, CD20 status, prior chemotherapy regimens, disease status, bone marrow involvement, cardiac function (left ventricular ejection fraction), hepatic function (bilirubin, ALT, AST), renal function (creatinine, creatinine clearance), pulmonary function (DLCO, FEV1, FVC), autologous graft characteristics (CD34+ cells/kg).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "sex"
        ],
        [
          "Race",
          "race"
        ],
        [
          "KPS",
          "Karnofsky performance score"
        ],
        [
          "Disease status at transplantation",
          "disease status"
        ],
        [
          "No. of prior therapies",
          "prior chemotherapy regimens"
        ]
      ],
      "remaining_reference_features": [
        "Received transplantation",
        "Eligible for study"
      ],
      "remaining_candidate_features": [
        "diagnosis",
        "CD20 status",
        "bone marrow involvement",
        "cardiac function (left ventricular ejection fraction)",
        "hepatic function (bilirubin, ALT, AST)",
        "renal function (creatinine, creatinine clearance)",
        "pulmonary function (DLCO, FEV1, FVC)",
        "autologous graft characteristics (CD34+ cells/kg)"
      ]
    }
  }
}